Course Information

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

PROGRAM OVERVIEW

Hereditary angioedema (HAE) is a rare autosomal-dominant disorder that affects approximately 1 in 50,000 people worldwide. Individuals with HAE typically experience recurrent painful swelling of the extremities, face, or genitals, in addition to gastrointestinal attacks and potentially fatal laryngeal edema. Furthermore, these swelling episodes are often associated with disfigurement, significant functional impairment, and decreased quality of life (QOL). Despite the existence of specific diagnostic criteria, diagnosis may be delayed by up to 15 years, leading to delays in optimal treatment with available on-demand and prophylactic therapies. Additionally, several novel agents are in development. Given the range of treatment options (eg, formulations, administration routes, dosing strategies), timely diagnosis and personalized treatment plans and a shared decision-making approach are essential to ensure appropriate utilization of prescribed treatment and quick recovery from attacks.

Join our expert faculty in this case-based activity to explore a tailored approach that not only enhances treatment adherence and efficacy but also significantly improves patient QOL, ensuring that clinicians can better address the complexities of HAE to promote improved health outcomes and reduced morbidity.

Learning Objectives

TARGET AUDIENCE

This educational activity has been designed to meet the needs of allergists, immunologists, nurse practitioners, physician assistants, and other healthcare providers who manage patients with HAE.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Apply guideline-recommended strategies to accurately identify patients with HAE
Analyze and compare approved and emerging treatment options for managing HAE effectively
Utilize shared decision-making and validated assessment tools in the development of treatment plans for patients with HAE

Faculty Information and Disclosures

FACULTY PRESENTERS

Maeve O’Connor, MD, FACAAI, FAAAAI, FACP
Clinical Assistant Professor, University of North Carolina – Charlotte Department of Public Health Sciences
Clinical Adjunct Professor, University of Arizona-Tucson
Department of Integrative Medicine
Medical Director, Integrative Allergy & Immunology Care, LLC
Medical Director and Principal Investigator, Allergy Asthma & Immunology Research Institute
Chief Medical Officer, Consortium of Independent Immunology Clinics
Chief Medical Officer, Alexander Innovations International

Nicholas C. Kolinsky, DO
Clinical Adjunct Faculty
Allergy and Immunology
Lincoln Memorial University
DeBusk College of Osteopathic Medicine
Harrogate, Tennessee

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Nicholas C. Kolinsky, DO
Advisory Boards: ADMA Biologics, AstraZeneca, Hikma Pharmaceuticals, KalVista Pharmaceuticals, Novartis Pharmaceuticals, Pharming
Speaker: Amgen, AstraZeneca, CSL Behring, GlaxoSmithKline, Hikma Pharmaceuticals, Sanofi Pharmaceuticals

Maeve O’Connor, MD, FACAAI, FAAAAI, FACP
Advisory Boards: ADMA, Amgen, AstraZeneca, Blueprint, Cogent, CSL Behring, GlaxoSmithKline, KalVista, Novartis, Optinose, Pharming, Regeneron, Sanofi, Takeda
Consultant/Speaker: ADMA, Amgen, AstraZeneca, Blueprint, Cogent, CSL Behring, GlaxoSmithKline, KalVista, Novartis, Optinose, Pharming, Regeneron, Sanofi, Takeda
Research: ADMA, Amgen, AstraZeneca, Blueprint, Cogent, CSL Behring, GlaxoSmithKline, KalVista, Novartis, Optinose, Pharming, Regeneron, Sanofi, Takeda

The Integrity CE, LLC planners and managers do not have any relevant financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:

Complete the pretest
View the live webcast
Complete the posttest and evaluation form at the end of the program

A statement of credit will be issued only upon receipt of a completed activity evaluation form. Certificates will be sent via email within four weeks of receipt of the competed evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below: Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Evolving Strategies for the Management of Hereditary Angioedema – A Patient-Centered Approach With Real-World Examples: Monday, July 21, 2025